Daptomycin

Lipopeptide Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Daptomycin is a drug in the Lipopeptide Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 2003. DrugCentral lists 1 molecular target, including ompD. Recorded indications include Bacteremia caused by Staphylococcus aureus, Complicated Skin and Skin Structure Enterococcus Faecalis Infection, Complicated Skin and Skin Structure Staphylococcus Aureus Infection and Complicated Skin and Skin Structure Streptococcus Agalactiae Infection.

• Drug class: Lipopeptide Antibacterial.
• Molecular targets: ompD (1 listed in DrugCentral).
• Indications: Bacteremia caused by Staphylococcus aureus, Complicated Skin and Skin Structure Enterococcus Faecalis Infection, Complicated Skin and Skin Structure Staphylococcus Aureus Infection, Complicated Skin and Skin Structure Streptococcus Agalactiae Infection and Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection and others.
• ATC code: J01XX09 (Other antibacterials).
• Molecular formula: C72H101N17O26; molecular weight 1620.69 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (12)

• Bacteremia caused by Staphylococcus aureus
• Complicated Skin and Skin Structure Enterococcus Faecalis Infection
• Complicated Skin and Skin Structure Staphylococcus Aureus Infection
• Complicated Skin and Skin Structure Streptococcus Agalactiae Infection
• Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection
• Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
• Right-sided Staphylococcus aureus endocarditis
• Secondary infection of erosion and ulcer caused by MRSA
• Secondary infection of surgical wounds caused by MRSA
• Secondary infection of trauma, and burn wounds caused by MRSA
• Sepsis caused by methicillin resistant Staphylococcus aureus
• Sepsis due to Staphylococcus aureus

Off-label uses (1)

• Diabetic Foot Infection Due to Gram-Positive Bacteria

Contraindications (7)

• Acute nephropathy
• Diarrhea
• Disorder of muscle
• Eosinophilic asthma
• Increased Creatine Phosphokinase
• Neuropathy
• Pseudomembranous enterocolitis

Mechanism & targets

• Established pharmacologic class: Lipopeptide Antibacterial

Molecular targets (1)

Target	Gene	Action	Activity
Outer membrane porin protein OmpD	ompD	unknown	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2011-07-01	PMDA	—	MSD K.K
2003-09-12	FDA	—	CUBIST

ATC classification

ATC code	Therapeutic hierarchy
J01XX09	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Other antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Eosinophilic pneumonia	3042.7
Eosinophilia	1185.8
Eosinophilic pneumonia acute	1174.3
Blood creatine phosphokinase increased	1011.9
Drug reaction with eosinophilia and systemic symptoms	869.6
Rhabdomyolysis	795.7
Product use in unapproved indication	690.5
Acute kidney injury	597.9
Pathogen resistance	525.0
Pneumonitis	446.6
Agranulocytosis	413.2
Antimicrobial susceptibility test resistant	408.1

Chemical structure

• Molecular formula: C₇₂H₁₀₁N₁₇O₂₆
• Molecular weight: 1620.69 g/mol
• CAS number: —
• InChIKey: DOAKLVKFURWEDJ-QCMAZARJSA-N
• PubChem CID: 21585658

CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Daptomycin used for?

DrugCentral lists the following indications for Daptomycin: Bacteremia caused by Staphylococcus aureus, Complicated Skin and Skin Structure Enterococcus Faecalis Infection, Complicated Skin and Skin Structure Staphylococcus Aureus Infection, Complicated Skin and Skin Structure Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection, Complicated Skin and Skin Structure Streptococcus Pyogenes Infection, Right-sided Staphylococcus aureus endocarditis and Secondary infection of erosion and ulcer caused by MRSA and others.

How does Daptomycin work?

Its molecular targets in DrugCentral include ompD.

When was Daptomycin first approved?

Daptomycin was first approved by the FDA in 2003.

What drug class does Daptomycin belong to?

Daptomycin is in the Lipopeptide Antibacterial class.

What is the chemical formula of Daptomycin?

Daptomycin has the molecular formula C72H101N17O26 and a molecular weight of 1620.69 g/mol.

Sources

• DrugCentral drug card 783 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL387675 — compound record and bioactivity
• PubChem CID 21585658 — chemical identifiers
• DrugBank DB00080 — drug record
• FDA UNII NWQ5N31VKK — substance identity
• DailyMed: FDA labels for Daptomycin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.